A message from WHA president, Danjuma Adda

28 July World Hepatitis Day 2023

Every year, more than a million lives are lost to hepatitis. We’re not waiting for change – we’re fighting to make it happen. 

The theme for World Hepatitis Day 2023 is “We’re not waiting”. It is an opportunity to celebrate the actions individuals take in their own lives everyday to protect themselves from the harms of hepatitis. This includes getting tested, starting treatment when their doctor recommends, protecting their family through antenatal screening, mothers starting treatment if they need it and ensuring their new born babies are vaccinated at birth. It is also a time to celebrate the incredible organisations around the world who “aren’t waiting” and are working tirelessly to eliminate hepatitis in their communities. They are the true heroes of the battle against hepatitis and the World Hepatitis Alliance is proud to stand should-to-shoulder with you in this fight.  

I am living with hepatitis B and I lost my mother to hepatitis C. If my mother had been diagnosed sooner she would probably be alive today but she was diagnosed too late. I became a hepatitis advocate as I didn’t want others to suffer the same pain I have had of losing loved ones whilst living with my hepatitis B diagnosis. I realised that, as a community, we need to raise awareness of this life-threatening disease. We needed to change the narrative about hepatitis. 

Since the last World Hepatitis Day, The Global Fund has made a commitment to expand support for hepatitis-related services which will bring hope for so many communities. Increased investment is vital to meet the World Health Organization’s 2030 elimination targets, we call on funders to integrate viral hepatitis into their programs for equitable and people-centered healthcare. 

Although there has been progress, we still face many challenges.  Liver cancer related to hepatitis is on the rise around the world, especially in low- and middle-income countries. Stigma and discrimination continue to be a barrier to testing and care; and globally more than 350 million people are still living with this life-threatening disease.  

In Africa, only 30% of countries have introduced the birth dose vaccine and only 6% of newborns receive a hepatitis B vaccine at birth.  

Last month, we received news that Gavi will be resuming their hepatitis B birth dose programme. We thank Gavi for this commitment and wait with interest for further clarity around the timings of the implementation.  

One of us dies every 30 seconds from a hepatitis related illness. But World Hepatitis Day is a next milestone on our journey towards hepatitis elimination.

I wish you a successful World Hepatitis Day. Thank you for your commitment. Hepatitis Can’t Wait! 
 
Danjuma Adda  
President, World Hepatitis Alliance 

 

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close